Track market-moving stories before they get noisy

The iShares U.S. Pharmaceuticals ETF (IHE -1.91%) offers concentrated, low-beta pharmaceutical exposure, while Invesco S&P 500 Equal Weight Health Care ETF (RSPH -2.56%) provides equal-weighted access to the broader healthcare sector at a slightly higher cost.

Both funds launched in 2006 and focus on the American healthcare landscape, but they differ significantly in their construction. iShares U.S. Pharmaceuticals ETF targets the pharmaceutical sub-sector using market-cap weighting, whereas Invesco S&P 500 Equal Weight Health Care ETF captures the entire S&P 500 healthcare sector, assigning roughly equal importance to each constituent.

Snapshot (cost & size)MetricIHERSPHIssueriSharesInvescoShare price$104.73 (as of 2026-08-27)$37.61 (as of 2026-08-27)Expense ratio0.37%0.4%1-yr return (as of 2026-08-27)50.0%29.0%Dividend yield1.4%0.6%Beta0.490.79AUM$1.8B$834.7MBeta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of the trading day on Aug. 27, 2026.

iShares U.S. Pharmaceuticals ETF is slightly more affordable with an expense ratio of 0.37% compared to 0.4% for Invesco S&P 500 Equal Weight Health Care ETF. Investors seeking income may also find the higher payout from the iShares fund more attractive.

Performance & risk comparisonMetricIHERSPHMax drawdown (5 yr)(16.0%)(22.0%)Growth of $1,000 over 5 years (total return)$1,771$1,242What's insideThe Invesco S&P 500 Equal Weight Health Care ETF holds 59 stocks, leaning entirely into the healthcare sector, although occasionally the fund will hold minor exposure to technology as well. Because it is equal-weighted, it avoids the concentration risk often found in cap-weighted sector funds. Its largest positions include Moderna Inc (MRNA -3.59%) at 4.4%, Veeva Systems Inc (VEEV -3.73%) at 2.5%, and Charles River Laboratories International (CRL -2.68%) at 2.2%. It was launched in 2006. Invesco S&P 500 Equal Weight Health Care ETF has paid $0.23 per share over the trailing 12 months, which on its recent ~$37.61 share price works out to a 0.6% yield.

The iShares U.S. Pharmaceuticals ETF focuses solely on healthcare, with 56 holdings, and is strictly concentrated in the domestic pharmaceutical industry. Unlike its competitor, this fund is market-cap weighted, leading to significant concentration in industry giants. Its largest positions include Johnson & Johnson (JNJ -2.22%) at 22.5%, Eli Lilly & Co(LLY -2.21%) at 20.5%, and Merck & Co. (MRK -1.24%) at 5%. It was launched in 2006. iShares U.S. Pharmaceuticals ETF has paid $1.47 per share over the trailing 12 months, which on its recent ~$104.73 share price works out to a 1.4% yield.

For more guidance on ETF investing, check out the full guide at this link.

Which looks like the better buy?Like most healthcare funds, each of these ETFs are completely invested in U.S. healthcare stocks.

But they have crucial differences investors might want to consider. IHE, the iShares healthcare fund, is mostly focused on large-cap stocks, with 59% of its portfolio dedicated to that style of equity. Just about 17% are in mid caps, all “value” stocks, and the balance are in small caps.

On the other hand, RSPH, the Invesco offering, is just 29% in large caps, with 53% of its holdings in mid caps and the balance in small caps.

The equal weighting of the Invesco fund also means it is more balanced throughout its holdings. The top 10 stocks in the ETF account for just about 23% of the portfolio. By comparison, the top 10 holdings of IHE account for 78% of its assets. That's a lot.

Still, it is hard to overlook the performance of the iShares ETF compared to its Invesco rival. IHE has beaten RSPH over the past three years and five years, returning 19.9% and 11.9%, respectively, compared to RSPH's annualized three-year returns of 9.6% and five-year returns of 5.2%.

Over the past decade, RSPH has been the better-performing ETF, returning 9.8% to IHE's 9.3%. The lower drawdown is a bonus for long-term investors, making IHE the pick for 2026.

Key Takeaways Veeva Systems beat Q2 estimates, raised its fiscal 2027 outlook and advanced Vault CRM adoption.VEEV has more than 180 Vault CRM customers live, with commitments from 12 of the top 20 biopharmas.Veeva Systems' AI push is advancing, but market saturation and competition could constrain CRM growth. Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.

This Zacks Rank #3 (Hold) company’s shares have gained 25.7% in the year-to-date period compared with 11.3% growth of the industry. The S&P 500 Composite has increased 10.8% during the said time frame.

The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $45.6 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.7%.

Reasons Favoring VEEV’s GrowthDiversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.  

Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.

Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continued to advance in the second quarter of fiscal 2027, when Veeva Systems recorded its best CRM quarter and added two top-20 biopharma selections. Management said that Veeva Systems now has 12 of the top 20 CRM commitments, with two decisions remaining, up from 10 wins in the prior quarter.

More than 180 customers are live on Vault CRM, and one top-20 customer has enabled AI across its full field force. Commercial subscription revenues rose 13% year over year to $347.4 million, with management citing growth across CRM, content, data, Crossix and Ostro. The expanding live base supports ongoing migrations and creates opportunities to attach adjacent commercial applications as customers consolidate workflows on Vault.

Strong Q2 Results: Veeva Systems exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.

Veeva Systems continued to make notable progress with Vault CRM. The platform recorded its best quarter ever, with more than 180 customers live, including five top 20 biopharmas. In August, two additional top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, taking total top 20 commitments to 12 globally. A top 20 biopharma also deployed Vault CRM and Agentic Call Report across its entire U.S. field team during the quarter.

The company also advanced its AI strategy. Veeva Falcon, its agentic labor platform for clinical, regulatory and safety functions, now has five early adopters and remains on track for initial go-lives this year. Veeva Systems also acquired Copli and launched Veeva Falcon MLR to automate content reviews.

Vault AI added new standard agents, enhanced existing agents and introduced advanced tools for custom agent development in August. Management noted that customer interest in Falcon remains high, although product readiness and work with early adopters remain key near-term priorities.

Image Source: Zacks Investment Research

Factor That May Offset VEEV’s GainsMarket Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.

Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.          

Estimate TrendVeeva Systems is witnessing a positive estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has moved 17 cents north to $9.22.

The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $933.8 million, indicating a 15.1% improvement from the year-ago quarter’s reported number. The consensus mark for fiscal third-quarter EPS is pegged at $2.33, implying a 14.2% improvement year over year.

Key PicksSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Michael Burry Takes Profits in Veeva. But He Has a Stark Warning for Snowflake Summary

Michael Burry trimmed his Veeva position after the shares rallied sharply while maintaining a bullish view on the software company

Michael Burry (Trades, Portfolio) has kept a bullish stance on Veeva Systems VEEV while reducing part of his holding after a rapid increase in the shares.

Burry disclosed the position earlier this year as part of a broader view that software stocks could recover. He later added to the investment before trimming it as Veeva approached a level he considered a potential barrier for further gains.

The move does not signal that Burry has abandoned the company. His comments indicate that valuation and the speed of the rally influenced the decision to reduce exposure rather than exit the investment.

Burry also raised concerns about Snowflake SNOW, describing its valuation as difficult to justify and pointing to potential long-term risks from cybersecurity developments involving artificial general intelligence and quantum computing.

Snowflake's shares, however, rose more than 23% in premarket trading after its latest results exceeded expectations. The company lifted its fiscal 2027 product-revenue forecast to $6.07 billion, representing 36% annual growth, from $5.84 billion previously.

Burry's Veeva trim may temper sentiment, while Snowflake's stronger outlook could offset valuation concerns.

Also check out:

Michael Burry Undervalued Stocks Michael Burry Top Growth Companies Michael Burry High Yield stocks, and Stocks that Michael Burry keeps buying Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

PLEASANTON, Calif., Sept. 2, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston, MA.

-  El sistema de seguridad Veeva Falcon funciona con todos los sistemas de seguridad compatibles con E2B en cualquier canal de admisión

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) anunció hoy Veeva Falcon Safety, un producto de operaciones de seguridad de agentes para optimizar la recepción de eventos adversos, el procesamiento de casos y el seguimiento, con el fin de reducir costes, aumentar la velocidad y mantener el cumplimiento normativo para empresas biofarmacéuticas de todos los tamaños.

Además de integrarse a la perfección con Veeva Safety, Falcon Safety se encargará de la gestión inicial y el seguimiento de cualquier sistema de seguridad compatible con E2B, incluidos Oracle Argus y ArisGlobal LifeSphere MultiVigilance.

"Hemos tenido el privilegio de colaborar estrechamente con gestores de casos, expertos en farmacovigilancia y especialistas en seguridad de todo el mundo para desarrollar Veeva Safety", declaró Marius Mortensen, vicepresidente de producto de Falcon en Veeva. "Con Falcon Safety, nos entusiasma consolidar esa colaboración para ayudar al sector a reinventar sus operaciones de seguridad".

Falcon Safety, cuya disponibilidad para los primeros usuarios está prevista para noviembre de 2026, forma parte de Veeva AI, la línea de soluciones de inteligencia artificial de Veeva específicas para el sector de las ciencias de la vida.

Acerca de Veeva Systems

Veeva ofrece la plataforma en la nube líder del sector para las ciencias de la vida, con aplicaciones, agentes, datos y consultoría. Comprometida con la innovación, la excelencia de sus productos y el éxito de sus clientes, Veeva presta servicios a más de 1.500 clientes, desde las mayores farmacéuticas del mundo hasta empresas biotecnológicas emergentes. Como corporación de beneficio público, Veeva se compromete a equilibrar los intereses de todas las partes interesadas, incluyendo clientes, empleados, accionistas y los sectores a los que sirve. Para más información, visite veeva.com.

Declaraciones prospectivas de Veeva

Este comunicado contiene declaraciones prospectivas sobre los productos y servicios de Veeva y los resultados o beneficios esperados derivados de su uso. Estas declaraciones se basan en nuestras expectativas actuales. Los resultados reales podrían diferir sustancialmente de los aquí expuestos y no tenemos obligación de actualizar dichas declaraciones. Existen numerosos riesgos que podrían afectar negativamente a nuestros resultados, incluidos los riesgos e incertidumbres descritos en nuestro informe 10-Q correspondiente al ejercicio fiscal finalizado el 31 de julio de 2026, que puede consultar aquí (en las páginas 33 y 34 encontrará un resumen de los riesgos que podrían afectar a nuestro negocio), y en nuestros informes posteriores presentados ante la SEC, a los que puede acceder en sec.gov.

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) hat heute Veeva Falcon Safety angekündigt – eine auf autonomen Agenten basierende Lösung für das Sicherheitsmanagement, die die Erfassung unerwünschter Ereignisse, die Fallbearbeitung und die Nachverfolgung optimiert, um Kosten zu senken, Prozesse zu beschleunigen und die Compliance für Biopharma-Unternehmen jeder Größe zu gewährleisten.

Neben der nahtlosen Zusammenarbeit mit Veeva Safety wird Falcon Safety das Erfassungs- und Nachverfolgungsmanagement für alle E2B-konformen Sicherheitssysteme bereitstellen, darunter Oracle Argus und ArisGlobal LifeSphere MultiVigilance.

„Wir hatten das Privileg, bei der Entwicklung von Veeva Safety eng mit Fallbearbeitern, Pharmakovigilanz-Experten und Sicherheitsspezialisten weltweit zusammenzuarbeiten", sagte Marius Mortensen, Vice President of Product bei Falcon, einem Unternehmen von Veeva. „Wir freuen uns, mit Falcon Safety auf dieser Partnerschaft aufzubauen, um die Branche dabei zu unterstützen, ihre Sicherheitsabläufe neu zu gestalten."

Falcon Safety soll im November 2026 für Early Adopters verfügbar sein und ist Teil von Veeva AI, den branchenspezifischen KI-Lösungen von Veeva für die Life-Sciences-Branche.

Informationen zu Veeva Systems
Veeva bietet die Branchen-Cloud für die Life-Sciences-Branche mit Anwendungen, Agenten, Daten und Beratung. Veeva hat sich der Innovation, der Produktqualität sowie dem Kundenerfolg verschrieben und betreut mehr als 1500 Kunden, von den weltweit größten Pharmaunternehmen bis hin zu aufstrebenden Biotech-Unternehmen. Als Public Benefit Corporation ist Veeva bestrebt, die Interessen aller Interessengruppen in Einklang zu bringen, darunter Kunden, Beschäftigte, Aktionäre sowie die Branchen, für die das Unternehmen tätig ist. Weitere Informationen finden Sie auf veeva.com.

Zukunftsgerichtete Aussagen von Veeva
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen zu den Produkten und Dienstleistungen von Veeva und den erwarteten Ergebnissen oder Vorteilen aus der Nutzung unserer Produkte und Dienstleistungen. Diese Aussagen beruhen auf unseren derzeitigen Erwartungen. Die tatsächlichen Ergebnisse können erheblich von den Angaben in dieser Pressemitteilung abweichen, und wir sind nicht verpflichtet, solche Aussagen zu aktualisieren. Es bestehen zahlreiche Risiken, die sich potenziell negativ auf unsere Ergebnisse auswirken können, darunter die Risiken und Ungewissheiten, die in unserem Formular 10-Q für das am 31. Juli 2026 endende Geschäftsjahr offengelegt wurden – dieses finden Sie hier (eine Zusammenfassung der Risiken, die sich auf unser Geschäft auswirken können, finden Sie auf den Seiten 33 und 34) – sowie in unseren nachfolgenden SEC-Einreichungen, auf die Sie unter sec.gov zugreifen können.

31.8.2026 19:03

Index Dow Jones -0,64 % na 53216,18 b. S&P 500 -0,47 % na 7675,22 b. Nasdaq Composite -0,34 % na 26311,38 b.

Závěr měsíce se nese v negativní náladě po vyostření konfliktu USA s Iránem, kdy po měsíční pauze znovu mluví zbraně. Cena ropy je na vzestupu po útoku USA na dvě odpaliště raket Iránu. WTI se obchoduje nad hranicí USD 85,5 při růstu 2,5 % a Brent pokořil cenovku USD 90. Z indexu S&P jako jediný roste sektor energií. Přibližně o 1,5 % posilují ExxonMobil i Chevron.

Citelnějším poklesem se obchoduje sektor utilit, kde klesá zejména Edison International (- 24 %) a PG&E Corp (- 19 %). Hlavním důvodem je kalifornská legislativa týkající se odpovědnosti energetických společností za škody při požárech. Kalifornie upravila návrh tak, že neobsahuje očekávanou ochranu utilit před žalobami pojišťoven.

Dnešek je pro Apple (- 1,8 %) posledním dnem pod vedením současného CEO. Tim Cook do vedení společnosti nastoupil v roce 2011. Pochlubit se může například uvedením Apple Watches, anebo AirPods. Cena akcie za jeho působení posílila o 2300 %.

Do nákupního módu se přepnulo Strategy (3,08 %). Společnost reportovala nákup celkem 4 603 Bitcoinů v celkovém objemu cca USD 370 mil.

Z indexu Dow Jones v zeleném teritoriu drží pouze sedm emisí na čele se Salesforce (1,8 %) a naopak nejvíce klesá Alphabet (- 2,2 %).

Index S&P 500 -0,47 % na 7675,22 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +1,1 % Komunikační služby -1,7 % Informační technologie +0 % Utility -1,4 % Nezbytná spotřeba -0,4 % Reality -1,3 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Tesla (TSLA) +5,0 % Edison International (EIX) -24 % Veeva Systems (VEEV) +4,3 % PG&E Corp (PCG) -19 % Crowdstrike Holdings (CRWD) +4,1 % Howmet Aerospace (HWM) -8,7 % Coinbase Global (COIN) +3,8 % Aon (AON) -7,4 % Deere (DE) +3,6 % Take-Two Interactive Software (TTWO) -6,6 %
Marek Kameništiak
Fio banka, a.s.
Prohlášení

Total Revenues of $928.0M, up 18% Year Over Year
Subscription Revenues of $766.8M, up 16% Year Over Year

, /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.

"AI is opening up the next big chapter for Veeva and life sciences," said CEO Peter Gassner. "Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients."

Fiscal 2027 Second Quarter Results:

Revenues: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year. Operating Income and Non-GAAP Operating Income:(1) Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year. Net Income and Non-GAAP Net Income:(1) Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year. Net Income per Share and Non-GAAP Net Income per Share:(1) For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago. "Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board," said CFO Brian Van Wagener. "We continue to execute well across the business while also accelerating innovation and progress in new growth areas."

Recent Highlights:

Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry's fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development. Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training. Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:

Total revenues between $932 and $935 million. Non-GAAP operating income between $417 and $420 million.(2) Non-GAAP fully diluted net income per share between $2.33 and $2.34.(2) Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

Total revenues between $3,682 and $3,687 million. Non-GAAP operating income of about $1,640 million.(2) Non-GAAP fully diluted net income per share of approximately $9.21.(2) Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva's investor relations website.

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled "Non-GAAP Financial Measures" and the tables entitled "Reconciliation of GAAP to Non-GAAP Financial Measures" below for details.

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva's expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled "Summary of Risk Factors" on pages 33 and 34 in our filing on Form 10-Q for the period ended April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:

Media Contact:

Gunnar Hansen

Maria Scurry

Veeva Systems Inc.

Veeva Systems Inc.

267-460-5839

781-366-7617

[email protected]

[email protected]

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

July 31,
2026

January 31,
2026

Assets

Current assets:

Cash and cash equivalents

$    1,812,012

$    1,421,233

Short-term investments

5,430,935

5,139,581

Accounts receivable, net

496,677

1,259,737

Unbilled accounts receivable

68,970

50,609

Prepaid expenses and other current assets

137,633

126,470

Total current assets

7,946,227

7,997,630

Property and equipment, net

79,483

70,261

Deferred costs, net

27,835

29,961

Lease right-of-use assets

129,320

75,626

Goodwill

492,991

439,877

Intangible assets, net

55,647

30,314

Deferred income taxes

268,250

273,417

Other long-term assets

60,470

62,257

Total assets

$    9,060,223

$    8,979,343

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$       35,977

$       37,644

Accrued compensation and benefits

42,188

45,857

Accrued expenses and other current liabilities

49,634

45,885

Income tax payable

3,018

6,698

Deferred revenue

1,310,498

1,488,819

Lease liabilities

14,635

12,153

Total current liabilities

1,455,950

1,637,056

Deferred income taxes

2,056

558

Long-term lease liabilities

137,060

83,706

Other long-term liabilities

33,708

43,271

Total liabilities

1,628,774

1,764,591

Stockholders' equity:

Common stock

2

2

Additional paid-in capital

2,579,728

2,843,089

Accumulated other comprehensive (loss) income

(46,147)

8,160

Retained earnings

4,897,866

4,363,501

Total stockholders' equity

7,431,449

7,214,752

Total liabilities and stockholders' equity

$    9,060,223

$    8,979,343

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Revenues:

Subscription(3)

$      766,764

$      659,183

$    1,496,939

$    1,293,951

Professional services and other(4)

161,199

129,898

313,972

254,173

Total revenues

927,963

789,081

1,810,911

1,548,124

Cost of revenues(5):

Cost of subscription

105,677

93,830

204,780

172,176

Cost of professional services and other

126,335

101,423

248,156

196,901

Total cost of revenues

232,012

195,253

452,936

369,077

Gross profit

695,951

593,828

1,357,975

1,179,047

Operating expenses(5):

Research and development

222,918

192,677

431,241

376,710

Sales and marketing

126,701

109,439

237,818

208,067

General and administrative

71,314

95,804

140,786

164,630

Total operating expenses

420,933

397,920

809,845

749,407

Operating income

275,018

195,908

548,130

429,640

Other income, net

74,512

69,456

148,930

134,545

Income before income taxes

349,530

265,364

697,060

564,185

Income tax provision

76,101

65,055

162,695

135,686

Net income

$      273,429

$      200,309

$      534,365

$      428,499

Net income per share:

Basic

$          1.68

$          1.23

$          3.28

$          2.63

Diluted

$          1.66

$          1.19

$          3.22

$          2.56

Weighted-average shares used to compute net income per share:

Basic

162,344

163,496

162,836

163,129

Diluted

165,057

167,685

166,072

167,272

Other comprehensive income:

Net change in unrealized (loss) gain on available-for-sale investments

$      (26,490)

$      (11,300)

$      (53,941)

$        6,067

Net change in cumulative foreign currency translation gain (loss)

135

390

(366)

352

Comprehensive income

$      247,074

$      189,399

$      480,058

$      434,918

(3) Includes subscription revenues from the following product areas:

Veeva Commercial Solutions

$      347,389

$      307,523

$      685,255

$      612,934

Veeva R&D and Quality Solutions

419,375

351,660

811,684

681,017

Total subscription

$      766,764

$      659,183

$    1,496,939

$    1,293,951

(4) Includes professional services and other revenues from the following product areas:

Veeva Commercial Solutions

$       59,742

$       47,703

$      117,315

$       94,270

Veeva R&D and Quality Solutions

101,457

82,195

196,657

159,903

Total professional services and other

$      161,199

$      129,898

$      313,972

$      254,173

(5) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription

$        2,224

$        1,941

$        3,985

$        3,656

Cost of professional services and other

15,939

14,804

30,090

27,573

Research and development

62,220

53,388

113,783

101,337

Sales and marketing

27,886

25,392

52,480

47,713

General and administrative

28,534

26,441

55,724

53,897

Total stock-based compensation

$      136,803

$      121,966

$      256,062

$      234,176

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Six months ended July 31,

2026

2025

Cash flows from operating activities

Net income

$     534,365

$     428,499

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

22,458

19,948

Reduction of lease right-of-use assets

7,038

6,316

Accretion of discount on short-term investments

(2,841)

(4,535)

Stock-based compensation

256,062

234,176

Amortization of deferred costs

9,805

8,205

Deferred income taxes

26,529

31,699

Other, net

(1,127)

(1,414)

Changes in operating assets and liabilities:

Accounts receivable

768,314

593,032

Unbilled accounts receivable

(18,361)

(9,587)

Deferred costs

(7,679)

(7,721)

Prepaid expenses and other current and long-term assets

(21,394)

(21,232)

Accounts payable

(652)

3,361

Accrued expenses and other current liabilities

(1,578)

23,763

Income tax payable

(3,945)

(5,362)

Deferred revenue

(200,001)

(180,888)

Lease liabilities

(4,426)

(5,300)

Other long-term liabilities

3,258

2,631

Net cash provided by operating activities

1,365,825

1,115,591

Cash flows from investing activities

Purchases of short-term investments

(1,706,632)

(1,452,857)

Maturities and sales of short-term investments

1,345,987

1,023,691

Long-term assets

(9,773)

(12,213)

Acquisitions, net of cash acquired

(81,833)

—

Net cash used in investing activities

(452,251)

(441,379)

Cash flows from financing activities

Proceeds from exercise of common stock options

17,143

182,297

Repurchases of common stock

(472,673)

—

Taxes paid related to net share settlement of equity awards

(66,304)

(46,228)

Net cash (used in) provided by financing activities

(521,834)

136,069

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(831)

1,365

Net change in cash, cash equivalents, and restricted cash

390,909

811,646

Cash, cash equivalents, and restricted cash at beginning of period

1,423,412

1,120,963

Cash, cash equivalents, and restricted cash at end of period

$   1,814,321

$   1,932,609

Supplemental disclosures of other cash flow information:

Excess tax (deficiency) benefit from employee stock plans

$        (824)

$      15,610

Non-GAAP Financial Measures

In Veeva's public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefit (deficiency). Excess tax benefits (deficiencies) from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva finds it useful to exclude excess tax benefits (deficiencies) when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits (deficiencies), Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies. Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva's management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies. Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva's management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva's revenues earned during the periods presented and will contribute to Veeva's future period revenues as well. Litigation settlement-related charges. We exclude certain costs related to litigation settlements, including outcome-based payments to the law firms that represented us, because they are non-recurring and outside the ordinary course of business. Because these costs are unrelated to our day-to-day business operations, we believe excluding them enables more consistent evaluation of our operating results. Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures. There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva's management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands)

(Unaudited)

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Net cash provided by operating activities on a GAAP basis

$    238,709

$    238,433

$  1,365,825

$  1,115,591

Excess tax (benefit) deficiency from employee stock plans

(3,268)

(13,031)

824

(15,610)

Net cash provided by operating activities on a non-GAAP basis

$    235,441

$    225,402

$  1,366,649

$  1,099,981

Net cash used in investing activities on a GAAP basis

$    (63,540)

$   (389,272)

$   (452,251)

$   (441,379)

Net cash (used in) provided by financing activities on a GAAP basis

$   (259,308)

$    115,689

$   (521,834)

$    136,069

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Cost of subscription revenues on a GAAP basis

$    105,677

$     93,830

$    204,780

$    172,176

Stock-based compensation expense

(2,224)

(1,941)

(3,985)

(3,656)

Amortization of purchased intangibles

(1,072)

(1,046)

(1,746)

(2,058)

Cost of subscription revenues on a non-GAAP basis

$    102,381

$     90,843

$    199,049

$    166,462

Gross margin on subscription revenues on a GAAP basis

86.2 %

85.8 %

86.3 %

86.7 %

Stock-based compensation expense

0.3

0.3

0.3

0.3

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on subscription revenues on a non-GAAP basis

86.6 %

86.2 %

86.7 %

87.1 %

Cost of professional services and other revenues on a GAAP basis

$    126,335

$    101,423

$    248,156

$    196,901

Stock-based compensation expense

(15,939)

(14,804)

(30,090)

(27,573)

Amortization of purchased intangibles

—

(139)

—

(273)

Cost of professional services and other revenues on a non-GAAP basis

$    110,396

$     86,480

$    218,066

$    169,055

Gross margin on professional services and other revenues on a GAAP basis

21.6 %

21.9 %

21.0 %

22.5 %

Stock-based compensation expense

9.9

11.4

9.5

10.8

Amortization of purchased intangibles

—

0.1

—

0.2

Gross margin on professional services and other revenues on a non-GAAP basis

31.5 %

33.4 %

30.5 %

33.5 %

Gross profit on a GAAP basis

$    695,951

$    593,828

$  1,357,975

$  1,179,047

Stock-based compensation expense

18,163

16,745

34,075

31,229

Amortization of purchased intangibles

1,072

1,185

1,746

2,331

Gross profit on a non-GAAP basis

$    715,186

$    611,758

$  1,393,796

$  1,212,607

Gross margin on total revenues on a GAAP basis

75.0 %

75.3 %

75.0 %

76.2 %

Stock-based compensation expense

2.0

2.1

1.9

2.0

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on total revenues on a non-GAAP basis

77.1 %

77.5 %

77.0 %

78.3 %

Research and development expense on a GAAP basis

$    222,918

$    192,677

$    431,241

$    376,710

Stock-based compensation expense

(62,220)

(53,388)

(113,783)

(101,337)

Amortization of purchased intangibles

(270)

—

(270)

—

Research and development expense on a non-GAAP basis

$    160,428

$    139,289

$    317,188

$    275,373

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Sales and marketing expense on a GAAP basis

$    126,701

$    109,439

$    237,818

$    208,067

Stock-based compensation expense

(27,886)

(25,392)

(52,480)

(47,713)

Amortization of purchased intangibles

(2,720)

(2,890)

(5,051)

(5,685)

Sales and marketing expense on a non-GAAP basis

$     96,095

$     81,157

$    180,287

$    154,669

General and administrative expense on a GAAP basis

$     71,314

$     95,804

$    140,786

$    164,630

Stock-based compensation expense

(28,534)

(26,441)

(55,724)

(53,897)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

General and administrative expense on a non-GAAP basis

$     42,780

$     38,736

$     85,062

$     80,106

Operating expense on a GAAP basis

$    420,933

$    397,920

$    809,845

$    749,407

Stock-based compensation expense

(118,640)

(105,221)

(221,987)

(202,947)

Amortization of purchased intangibles

(2,990)

(2,890)

(5,321)

(5,685)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

Operating expense on a non-GAAP basis

$    299,303

$    259,182

$    582,537

$    510,148

Operating income on a GAAP basis

$    275,018

$    195,908

$    548,130

$    429,640

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Operating income on a non-GAAP basis

$    415,883

$    352,576

$    811,259

$    702,459

Operating margin on a GAAP basis

29.6 %

24.8 %

30.3 %

27.8 %

Stock-based compensation expense

14.7

15.5

14.1

15.1

Amortization of purchased intangibles

0.5

0.5

0.4

0.5

Litigation settlement-related charges

—

3.9

—

2.0

Operating margin on a non-GAAP basis

44.8 %

44.7 %

44.8 %

45.4 %

Net income on a GAAP basis

$    273,429

$    200,309

$    534,365

$    428,499

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Income tax effect on non-GAAP adjustments(6)

(26,882)

(23,572)

(38,945)

(40,085)

Net income on a non-GAAP basis

$    387,412

$    333,406

$    758,549

$    661,234

Diluted net income per share on a GAAP basis

$        1.66

$        1.19

$        3.22

$        2.56

Stock-based compensation expense

0.83

0.73

1.54

1.40

Amortization of purchased intangibles

0.02

0.02

0.04

0.05

Litigation settlement-related charges

—

0.18

—

0.18

Income tax effect on non-GAAP adjustments(6)

(0.16)

(0.13)

(0.23)

(0.24)

Diluted net income per share on a non-GAAP basis

$        2.35

$        1.99

$        4.57

$        3.95

________________________
(6) For the three and six months ended July 31, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%.

SOURCE Veeva Systems

Veeva Systems (VEEV - Free Report) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $1.99 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.86%. A quarter ago, it was expected that this provider of cloud-based software services for the life sciences industry would post earnings of $2.13 per share when it actually produced earnings of $2.24, delivering a surprise of +5.16%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Veeva, which belongs to the Zacks Medical Info Systems industry, posted revenues of $927.96 million for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.64%. This compares to year-ago revenues of $789.08 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Veeva shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 12.2%.

What's Next for Veeva?While Veeva has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Veeva was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.28 on $918.02 million in revenues for the coming quarter and $9.05 on $3.64 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Phreesia (PHR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended July 2026. The results are expected to be released on September 2.

This developer of health care software is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +1000%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Phreesia's revenues are expected to be $129.63 million, up 10.6% from the year-ago quarter.

Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of TruthVeeva Systems NYSE: VEEV reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud momentum and growing customer interest in its AI offerings.

The quarter ended July 31, 2026, and the company said it raised its guidance for the fiscal year. Chief Financial Officer Brian Van Wagener said commercial subscription revenue increased about 13% year over year, with double-digit growth even excluding Crossix.

Get Veeva Systems alerts:

Commercial growth broad-based Down 20%+, These 3 Software Stocks Are Boosting BuybacksVan Wagener said commercial-cloud growth was not driven by a single offering. Instead, performance was broad-based across CRM, content, data products, Crossix and Ostro. Crossix continued to have “a lot of headroom for growth,” he said, while CRM revenue continued to grow despite prior investor concerns that the category could decline.

Veeva’s commercial performance also reflected new customers and brands in Data Cloud, growth in Crossix measurement and audiences, and demand for CRM add-ons and content products, according to Van Wagener.

Veeva Systems: Increasing NDR and Other WinsPaul Shawah, Veeva’s executive vice president of strategy, said the company had an “exceptional” CRM quarter, citing Vault CRM selections by Eli Lilly, Biogen and Regeneron. He attributed the wins to customer trust in Veeva’s ability to deliver and to product performance. Shawah said Veeva has commitments from 12 of the top 20 biopharma companies, with two remaining decisions expected by the end of the year.

Management also discussed customers that previously chose Salesforce over Veeva CRM. Gassner said a handful of large customers selected Salesforce, in some cases about two years ago, but those implementations have encountered delays and challenges because of the complexity of the product. He said Veeva believes it could win back some of those customers, potentially in full or in selected regions, with most potential win-backs occurring in 2027 and 2028.

“We want to be your plan B,” Gassner said of Veeva’s discussions with those customers. Veeva CRM remains available as a backstop through the end of 2029, he noted.

Falcon AI becomes a key focus Gassner described Veeva Falcon as a new category for the company: “agentic labor.” Unlike Veeva’s traditional cloud software, data and consulting businesses, Falcon is intended to perform work through AI agents. He said customer interest is high, particularly because organizations see potential for cost savings, compliance improvements and greater efficiency.

However, Gassner said Veeva is currently the limiting factor because it needs to further prepare the product and work with early adopters. He emphasized that Falcon deployments should not require the extensive data mapping, system cutovers or extract-transform-load work often associated with enterprise software implementations.

Veeva expects Falcon sales to be directed primarily toward business-unit leaders and operations executives rather than IT departments. Gassner said the company’s initial focus is on life-sciences sponsors, though service providers have also expressed interest. He said Falcon could eventually be used by outsourced service providers, but Veeva is prioritizing sponsor use cases first.

On regulatory requirements, Gassner said agentic labor is non-deterministic and therefore requires training and guardrails similar to those used for human workers. Falcon includes human-in-the-loop capabilities that let users review an agent’s work within a Vault application, he said.

Management did not provide detailed Falcon pricing. Gassner said customers want predictable costs, and Veeva could use enterprise subscription agreements based on the size of a customer or its functional organization. Pricing could increase as Falcon’s capabilities mature, he added.

Gassner said he expects Falcon’s gross margins to be broadly similar to Veeva’s software margins over time. He said Veeva is placing more functionality in deterministic software layers and expects AI-model costs to decline over time through hardware improvements, open-weight models or other technology advances.

R&D portfolio shifts toward newer products Van Wagener said Veeva’s R&D business is in the middle of a transition from established products toward newer growth offerings. Earlier growth was supported by products including eTMF, CTMS, QualityDocs, Veeva QMS and the company’s regulatory suite.

Looking further out, Veeva sees growth opportunities in Veeva EDC, eCOA, RTSM, Safety and LIMS. Van Wagener described each as a large and strategic market opportunity, though all remain relatively early in their development cycles. He said the timing of their growth curves does not align exactly, which is reflected in the company’s outlook for the rest of the fiscal year.

Gassner said Veeva has EDC relationships with nine of the top 20 biopharma companies. He characterized EDC implementations as long-cycle projects and said the company expects continued progress over the next several years. Veeva is also expanding its clinical portfolio with site solutions and eSource capabilities.

Aspen and data-cloud strategy Veeva also discussed Aspen, its emerging horizontal CRM initiative. Gassner called Aspen a startup within Veeva, operating with small investment levels and focused on early customers and rapid product iteration. He said the company is targeting nimble technology startups initially and is confident there is demand for a new approach to horizontal CRM.

Aspen’s public pricing model is designed to be simpler and more predictable than traditional enterprise software pricing, according to Gassner. The company has discussed a price of $50 per user per month, with potential overage charges for unusual levels of data storage or compute usage.

Gassner said Aspen aims to address concerns around unpredictable pricing, vendor dependability, scalability, heavy data-entry requirements and lengthy CRM implementations. He said AI could reduce much of the data entry required in existing CRM systems.

In Data Cloud, Veeva said OpenData, Compass and Link are key areas of progress. Gassner described OpenData as clean reference data, Compass as particularly useful in certain complex-therapy markets, and Link as a market-leading product with expansion opportunities in medical insights, key accounts and congress workflows. While data products tend to grow gradually, he said they are strategically valuable because they work alongside Veeva’s applications, consulting services and AI agents.

Management also said its partnership with IQVIA has been productive. Gassner said customers appreciate reduced friction in working with the two companies and that greater collaboration across software, data and services could benefit the life-sciences industry.

About Veeva Systems (NYSE:VEEV)Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Veeva Systems Right Now?Before you consider Veeva Systems, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veeva Systems wasn't on the list.

While Veeva Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

770 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Veeva Systems Inc. (NYSE:VEEV) posted better-than-expected second-quarter results after Wednesday’s closing bell.

Veeva Systems reported quarterly earnings of $2.35 per share, which beat the consensus estimate of $2.22 by 5.86%, according to Benzinga Pro data. Quarterly revenue clocked in at $927.96 million, which beat the Street estimate of $905.28 million.

CEO Peter Gassner said, "Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients."

Veeva Systems raised its fiscal 2027 adjusted EPS guidance from $9.05 to $9.21, versus the $9.06 analyst estimate, and raised its revenue outlook to between $3.682 billion and $3.687 billion, versus the $3.65 billion estimate.

Veeva shares jumped 11.5% to $273.00 in pre-market trading.

These analysts made changes to their price targets on Veeva following earnings announcement.

Piper Sandler analyst Billy Fitzsimmons maintained the stock with an Overweight rating and raised the price target from $295 to $320. Needham analyst Ryan MacDonald maintained the stock with a Buy and raised the price target from $270 to $310. Evercore ISI Group analyst Kirk Materne maintained the stock with an In-Line rating and raised the price target from $185 to $250. Truist Securities analyst Jailendra Singh maintained the stock with a Buy and raised the price target from $262 to $305. Morgan Stanley analyst Craig Hettenbach maintained the stock with an Equal-Weight rating and raised the price target from $215 to $275. Trending

Considering buying VEEV stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways Veeva called Q2 its best CRM quarter ever, with more than 180 Vault CRM customers live. Falcon has five early adopters, with initial go-lives expected this year as AI demand builds. Fiscal 2027 revenue guidance is $3.682B-$3.687B, with non-GAAP EPS of about $9.21. Veeva Systems Inc. (VEEV - Free Report) used its fiscal second-quarter 2027 earnings call to emphasize accelerating AI development through Veeva Falcon and strengthening Vault CRM adoption across large biopharma customers.

Management balanced enthusiasm around new AI markets with execution caution, while stronger operating results supported higher fiscal 2027 guidance.

VEEV Puts Falcon at Center of AI PushFounder and CEO Peter Gassner said customer interest in Falcon, Veeva’s agentic labor platform, is high as customers prioritize efficiency, compliance and cost savings. He added that Veeva is currently the rate limiter as the product moves through early adoption.

A Baird analyst asked about early demand. Gassner said the company has five early adopters and expects initial go-lives this year, while noting Falcon avoids much of the implementation work associated with traditional software projects.

A Truist analyst pressed on pricing. Gassner said customers want predictability and discussed enterprise subscription structures that could rise as Falcon capabilities mature, while stressing that product readiness remains the priority.
Veeva CRM Execution Raises Competitive Stakes

Gassner called the second quarter Veeva’s best CRM quarter ever. More than 180 Vault CRM customers are live, while August commitments brought the number of top 20 biopharmas committed to Vault CRM to 12.

A Barclays analyst asked about customers that previously selected Salesforce. Gassner said some large projects are facing delays and implementation problems and said Veeva could win some of those customers back in 2027 and 2028.

VEEV Raises Outlook on Broad Commercial StrengthCFO Brian Van Wagener said Commercial subscription revenues rose about 13% year over year and remained in double digits excluding Crossix. He described strength across CRM, content, Data Cloud, Crossix and other offerings.

Non-GAAP earnings were $2.35 per share, which beat the Zacks Consensus Estimate of $2.22. Revenues were $928 million compared with the Zacks Consensus Estimate of $904.07 million. Total revenues increased 18% year over year.

Veeva expects fiscal third-quarter revenues in the range of $932 million-$935 million and non-GAAP earnings in the band of $2.33-$2.34. Fiscal 2027 revenue guidance is $3.682 billion-$3.687 billion, with non-GAAP earnings of about $9.21.

Veeva Sees R&D Growth Transition UnderwayVan Wagener said the R&D business is shifting from older drivers such as eTMF, CTMS, QDocs, QMS and regulatory products toward EDC, eCOA, RTSM, Safety and LIMS.

A Citi analyst asked when those newer products could create a clearer growth inflection. Van Wagener declined to provide year-by-year timing but said all five are large, strategic opportunities at relatively early stages.

Van Wagener added that the product S-curves do not line up perfectly, which is reflected in the balance-of-year outlook, while management remains confident in the longer-term R&D trajectory.

VEEV Keeps Aspen Early and Investment LightGassner described Aspen, Veeva’s horizontal CRM initiative, as a start-up inside the company. He said the investment is small relative to Veeva and no Aspen revenues are included in current plans.

An RBC analyst asked about pricing. Gassner said Aspen is designed around a simpler $50-per-user monthly price, with usage overages while keeping spending mostly predictable.

Asked by Citi about the early customer profile, Gassner pointed to nimble companies, including young technology start-ups. Veeva is focused on product quality and early-customer iteration rather than near-term contribution.

Veeva Stays Focused on ExecutionManagement’s tone was confident on CRM execution and customer demand for AI, but more measured on how quickly Falcon and Aspen can scale. Gassner repeatedly tied the opportunity to product readiness and successful customer go-lives.

Van Wagener said investment will scale with revenues and there is nothing material to call out for fiscal 2027 beyond what is already included in guidance.

VEEV Rank and Style Scores Send Mixed SignalsVEEV carries a Zacks Rank #4 (Sell), with a Value Score of C, Growth Score of A, Momentum Score of A and a VGM Score of B. The Style Scores favor growth and momentum characteristics, but Zacks methodology places greater weight on the Rank for near-term prospects.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks research emphasizes that favorable Style Scores complement, rather than override, a weak Zacks Rank. The Rank can change as analyst earnings estimates are revised following the just-reported results.

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals

Veeva Systems (VEEV -1.93%) stock is seeing big gains this week following the publication of the company's second-quarter report. Heading into this Friday's market open, the company's share price was up 13.8% from its level at the previous week's market close. b

After Wednesday's market close, Veeva Systems published results for the second quarter of its 2027 fiscal year -- which ended July 31. The company posted fiscal Q2 results that beat Wall Street's forecasts, and the company also issued stronger-than-expected forward guidance.

Image source: Getty Images.

Veeva Systems served up strong Q2 print Veeva's fiscal Q2 results came in significantly ahead of Wall Street's targets, with non-GAAP (adjusted) earnings per share of $2.35 on sales of $928 million surpassing the average analyst forecast for adjusted per-share earnings of $2.22 on sales of roughly $905.3 million. Overall revenue was up roughly 18% year over year, subscription revenue was up roughly 16%, and adjusted earnings per share rose approximately 18% compared to the prior-year period.

Premium Feature

Moneyball Superscore

84/100

Today's Change

(

-1.93

%) $

-5.44

Current Price

$

276.69

What's next for Veeva? For the current fiscal year, Veeva is targeting sales between $3.682 billion and $3.687 billion -- exceeding the average analyst estimate's call for revenue of $3.65 billion. Meanwhile, the company's guide for adjusted earnings per share of $9.21 for the year significantly surpassed the average analyst target for earnings per share of $9.06.

Along with the beats in fiscal Q2, strong forward guidance has spurred a significant uptick in bullish sentiment on the stock. Veeva's artificial intelligence technologies appear to be powering real performance improvements, and encouraging results for its Vault CRM and Falcon offerings suggest a strong near-term outlook.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Veeva Systems. The Motley Fool has a disclosure policy.

24.8.2026 10:55

Přestože je hlavní výsledková sezóna za námi, tak tento týden nabídne řadu zajímavých reportů. Tuzemští investoři se zaměří na pololetní čísla pojišťovny VIG, zatímco celý svět bude sledovat středeční výsledky NVIDIE (po trhu). V indexu S&P 500 zveřejní tento týden výsledky celkem 18 společností. O poptávce po polovodičích napoví také čísla společnosti Marvell Technology, která minulý týden zaujala oznámením o rozšířené spolupráci s Googlem. Pod drobnohledem budou i čísla řady softwarových firem, u nichž panují obavy z dopadu AI na jejich byznys. Patří mezi ně například Salesforce, Intuit, Veeva Systems, Autodesk či Workday.

Přehled vybraných společností reportujících své výsledky v tomto týdnu (zdroj: síť X - Earnings Whispers)

Úterý (25. srpna) USA (před trhem): Dick's Sporting Goods

USA (po trhu): Intuit, Zoom Video Communications

Středa (26. srpna) ČR (před trhem): VIG

USA (před trhem): Williams-Sonoma, J. M. Smucker

USA (po trhu): NVIDIA, CrowdStrike Holdings, Salesforce, Synopsys, Agilent Technologies, Veeva Systems, Hewlett-Packard (HP), Everpure, Okta

Čtvrtek (27. srpna) USA (před trhem): Dollar General, Dollar Tree, Best Buy, Hormel Foods

USA (po trhu): Marvell Technology, Autodesk, Workday, Ulta Beauty, IREN

Jako každé čtvrtletí jsme pro vás připravili podrobný kalendář pro ČR, USA a eurozónu.

Zdroj: Bloomberg, Earnings Whispers

Michal Bárta
Fio banka, a.s.
Prohlášení

Veeva Systems (VEEV - Free Report) ended the recent trading session at $242.75, demonstrating a +1.85% change from the preceding day's closing price. This change outpaced the S&P 500's 0.69% loss on the day. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, lost 1.33%.

Coming into today, shares of the provider of cloud-based software services for the life sciences industry had gained 20.73% in the past month. In that same time, the Medical sector gained 2.6%, while the S&P 500 gained 3.96%.

Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. The company's earnings report is set to go public on August 26, 2026. It is anticipated that the company will report an EPS of $2.22, marking a 11.56% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $904.07 million, reflecting a 14.57% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $9.05 per share and a revenue of $3.64 billion, signifying shifts of +11.73% and +13.96%, respectively, from the last year.

It is also important to note the recent changes to analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Veeva Systems is currently sporting a Zacks Rank of #3 (Hold).

From a valuation perspective, Veeva Systems is currently exchanging hands at a Forward P/E ratio of 26.34. This expresses no noticeable deviation compared to the average Forward P/E of 26.34 of its industry.

Investors should also note that VEEV has a PEG ratio of 0.75 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. VEEV's industry had an average PEG ratio of 1.73 as of yesterday's close.

The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Veeva Systems (VEEV - Free Report) closed at $241.51 in the latest trading session, marking a +2.08% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.54%.

The stock of provider of cloud-based software services for the life sciences industry has risen by 22.52% in the past month, leading the Medical sector's gain of 2.89% and the S&P 500's gain of 2.13%.

The upcoming earnings release of Veeva Systems will be of great interest to investors. The company's earnings report is expected on August 26, 2026. The company is expected to report EPS of $2.22, up 11.56% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $904.07 million, indicating a 14.57% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $9.05 per share and revenue of $3.64 billion, indicating changes of +11.73% and +13.96%, respectively, compared to the previous year.

Investors should also pay attention to any latest changes in analyst estimates for Veeva Systems. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Right now, Veeva Systems possesses a Zacks Rank of #3 (Hold).

With respect to valuation, Veeva Systems is currently being traded at a Forward P/E ratio of 26.15. Its industry sports an average Forward P/E of 28.71, so one might conclude that Veeva Systems is trading at a discount comparatively.

One should further note that VEEV currently holds a PEG ratio of 0.75. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 3.13.

The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 160, which puts it in the bottom 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Veeva Systems (VEEV - Free Report) closed at $217.80 in the latest trading session, marking a +2.01% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.18%. Elsewhere, the Dow lost 0.85%, while the tech-heavy Nasdaq lost 0.06%.

Prior to today's trading, shares of the provider of cloud-based software services for the life sciences industry had gained 13.47% outpaced the Medical sector's loss of 1.42% and the S&P 500's gain of 3.33%.

Investors will be eagerly watching for the performance of Veeva Systems in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 26, 2026. On that day, Veeva Systems is projected to report earnings of $2.22 per share, which would represent year-over-year growth of 11.56%. Alongside, our most recent consensus estimate is anticipating revenue of $904.07 million, indicating a 14.57% upward movement from the same quarter last year.

VEEV's full-year Zacks Consensus Estimates are calling for earnings of $9.05 per share and revenue of $3.64 billion. These results would represent year-over-year changes of +11.73% and +18.22%, respectively.

Investors might also notice recent changes to analyst estimates for Veeva Systems. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Veeva Systems holds a Zacks Rank of #3 (Hold).

Looking at its valuation, Veeva Systems is holding a Forward P/E ratio of 23.6. This indicates a discount in contrast to its industry's Forward P/E of 27.07.

We can additionally observe that VEEV currently boasts a PEG ratio of 0.67. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 3.35.

The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 68, finds itself in the top 28% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Posted by Defense World Staff on Aug 4th, 2026

Bangor Savings Bank purchased a new position in Veeva Systems Inc. (NYSE:VEEV – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,051 shares of the technology company’s stock, valued at approximately $896,000.

Other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in Veeva Systems by 7.0% in the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock worth $727,513,000 after acquiring an additional 271,252 shares in the last quarter. State Street Corp boosted its position in shares of Veeva Systems by 2.4% in the fourth quarter. State Street Corp now owns 3,589,425 shares of the technology company’s stock worth $801,267,000 after purchasing an additional 85,695 shares during the period. Geode Capital Management LLC boosted its position in shares of Veeva Systems by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company’s stock worth $706,442,000 after purchasing an additional 23,117 shares during the period. AQR Capital Management LLC increased its stake in shares of Veeva Systems by 31.2% in the third quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock worth $706,078,000 after purchasing an additional 574,164 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Veeva Systems by 12.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,728,089 shares of the technology company’s stock worth $385,761,000 after purchasing an additional 189,093 shares in the last quarter. Institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades Several analysts have recently commented on the stock. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of Veeva Systems in a research report on Thursday, June 4th. Raymond James Financial reiterated an “outperform” rating and issued a $225.00 price target on shares of Veeva Systems in a research note on Thursday, June 4th. Barclays decreased their price target on Veeva Systems from $250.00 to $235.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Zacks Research lowered Veeva Systems from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Veeva Systems in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.08.

Check Out Our Latest Research Report on Veeva Systems

Veeva Systems Trading Up 1.1% Shares of Veeva Systems stock opened at $206.11 on Tuesday. The firm has a market cap of $33.48 billion, a PE ratio of 36.74, a PEG ratio of 0.88 and a beta of 0.94. The stock has a 50 day moving average of $179.48 and a 200 day moving average of $179.88. Veeva Systems Inc. has a 12 month low of $148.05 and a 12 month high of $310.50.

Veeva Systems (NYSE:VEEV – Get Free Report) last released its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. The business had revenue of $882.95 million for the quarter, compared to the consensus estimate of $857.73 million. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.97 EPS. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, equities research analysts forecast that Veeva Systems Inc. will post 6.65 earnings per share for the current fiscal year.

About Veeva Systems (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Featured Stories Five stocks we like better than Veeva Systems SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks? Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of America Corp DE Buys 1,504,075 Shares of Webster Financial Corporation $WBS

Veeva Systems (VEEV - Free Report) closed at $201.56 in the latest trading session, marking a -3.05% move from the prior day. This move lagged the S&P 500's daily gain of 1.66%. Meanwhile, the Dow experienced a rise of 1.19%, and the technology-dominated Nasdaq saw an increase of 2.78%.

Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 12.86% over the past month, outpacing the Medical sector's gain of 0.54% and the S&P 500's loss of 1.49%.

Investors will be eagerly watching for the performance of Veeva Systems in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.22, marking a 11.56% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $904.07 million, up 14.57% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of $9.05 per share and revenue of $3.64 billion, which would represent changes of +11.73% and +13.96%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Veeva Systems. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Veeva Systems is currently sporting a Zacks Rank of #3 (Hold).

From a valuation perspective, Veeva Systems is currently exchanging hands at a Forward P/E ratio of 22.98. This valuation marks a discount compared to its industry average Forward P/E of 25.68.

Also, we should mention that VEEV has a PEG ratio of 0.66. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical Info Systems industry stood at 3.35 at the close of the market yesterday.

The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 72, finds itself in the top 30% echelons of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

32.78K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MO, BTI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Veeva Systems stands out as a compelling buy amid a potential market rotation into lagging software stocks. VEEV benefits from a highly regulated customer base, strong growth and margin profile, and robust sales execution. After a near-20% YTD decline and recent post-earnings volatility, VEEV's valuation is now especially attractive.

Veeva Systems (VEEV - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this provider of cloud-based software services for the life sciences industry have returned +14.4%, compared to the Zacks S&P 500 composite's +0.4% change. During this period, the Zacks Medical Info Systems industry, which Veeva falls in, has gained 8.6%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Veeva is expected to post earnings of $2.22 per share, indicating a change of +11.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $9.05 points to a change of +11.7% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $9.9 indicates a change of +9.4% from what Veeva is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Veeva is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Veeva, the consensus sales estimate for the current quarter of $904.07 million indicates a year-over-year change of +14.6%. For the current and next fiscal years, $3.64 billion and $4.07 billion estimates indicate +14% and +11.7% changes, respectively.

Last Reported Results and Surprise HistoryVeeva reported revenues of $882.95 million in the last reported quarter, representing a year-over-year change of +16.3%. EPS of $2.24 for the same period compares with $1.97 a year ago.

Compared to the Zacks Consensus Estimate of $857.33 million, the reported revenues represent a surprise of +2.99%. The EPS surprise was +5.16%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Veeva is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Veeva. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Veeva Systems (VEEV - Free Report) Veeva Systems Inc. is headquartered in Pleasanton, CA and provides industry cloud solutions for the global life sciences market. Its offerings span cloud software, data, artificial intelligence capabilities and business consulting, supporting customers from research and development through commercialization. Veeva operates as a single reportable segment and groups revenues into Commercial Solutions and R&D and Quality Solutions. 

VEEV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. VEEV has a Growth Style Score of B, forecasting year-over-year earnings growth of 11.7% for the current fiscal year.

For fiscal 2027, 10 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.19 to $9.05 per share. VEEV boasts an average earnings surprise of +5.5%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, VEEV should be on investors' short list.